Innate Pharma S.A. (IPHA)
Develops experimental cancer immunotherapy drugs that harness the body's natural killer cells.
$1.68-0.05%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-21.8%
The outlook
IPHA is trading below both its 50- and 200-day moving averages, positioned in the lower third of its 52-week range. Analyst sentiment leans bearish overall, though the average price target sits roughly 257% above the current price, reflecting a wide gap between current valuation and consensus long-term views.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range35% of the way from its 52-week low to high
Price targetAvg target +257% vs current price
Analyst price target
~12-month · 4 analysts$6.00average target+257.1% vs now
Now $1.68
Low $3.00High $8.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$157.8M
52-wk high
$2.63
52-wk low
$1.17
50-day avg
$1.83
200-day avg
$1.74
Trailing P/E
—